Edesa Biotech, Inc. (NASDAQ:EDSA) Short Interest Update

Edesa Biotech, Inc. (NASDAQ:EDSA) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 16,900 shares, an increase of 259.6% from the January 15th total of 4,700 shares. Based on an average daily trading volume, of 27,200 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.7% of the company’s stock are short sold.

Edesa Biotech Price Performance

NASDAQ:EDSA traded up $1.85 during mid-day trading on Thursday, reaching $3.71. The stock had a trading volume of 78,619,056 shares, compared to its average volume of 2,037,212. The stock has a market cap of $12.87 million, a P/E ratio of -1.97 and a beta of 0.85. The business’s 50 day moving average is $1.84 and its 200 day moving average is $3.13. Edesa Biotech has a fifty-two week low of $1.55 and a fifty-two week high of $5.99.

Edesa Biotech (NASDAQ:EDSA) last released its quarterly earnings data on Friday, December 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.25. Equities analysts expect that Edesa Biotech will post -1.75 EPS for the current year.

Edesa Biotech Company Profile

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.